Reportlinker Adds Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Advertisement

Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0546796/Testicular-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Advertisement

Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global testicular cancer market. The report identifies the key trends shaping and driving the global testicular cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global testicular cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global testicular cancer therapeutics market was valued at $91m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 3.8% over the next seven years, to reach $118m by 2017. The gradual growth of the market is primarily attributed to the expected continued domination of generics in the testicular cancer therapeutics market, as no disease-modifying molecule is expected to launch during the forecast period of 2017.

Scope

The report provides information on the key drivers and challenges of the testicular cancer therapeutics market. Its scope includes -

- Annualized global testicular cancer therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. No molecules are present in Phase III stage of clinical trial.Two molecules are present in Phase II and one is in Phase I. Two molecules are first-in-class and one is me-too. The first-in-class molecules come under the category of cyclin-dependent kinase inhibitors, and the me-too molecule has DNA alkylating activity. The participation of companies in clinical trials for testicular cancer therapeutics is not significant

- Analysis of the current and future competition in the global testicular cancer therapeutics market. The competition in the testicular cancer therapeutics market is weak. The market is dominated by generics such as etoposide, ifosfamide, cisplatin, bleomycin sulfate, gemicitabine, carboplatin and oxaliplatin. ZIOPHARM Oncology Inc. is the only company with a molecule in the clinical pipeline for testicular cancer therapeutics. Very few companies are investing in R&D for testicular cancer.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the testicular cancer therapeutics market.

- Analysis of key recent licensing and partnership agreements in testicular cancer therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global testicular cancer market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global testicular cancer market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global testicular cancer market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Overview 6

2.1.1 Histological Classification of Testicular Tumors Based on WHO 6

2.2 Epidemiology 7

2.3 Etiology and Pathophysiology 7

2.4 Risk Factors 8

2.5 Signs and Symptoms 8

2.6 Diagnosis 9

2.6.1 Physical Examination and History 9

2.6.2 Biopsy 9

2.6.3 Blood Test 9

2.6.4 Imaging Techniques 9

2.7 Staging 10

2.7.1 Testicular Cancer can be Categorized as Being in one of These Stages 13

2.7.2 Recurrent Testicular Cancer: 13

2.8 Survival Rate by Stage 14

2.9 Treatment and Management Pattern 15

2.9.1 Three Types of Standard Treatment are used: 15

2.9.2 Management of CIS and Germ Cell Tumors 15

2.9.3 Treatment Options by Stage 16

2.9.4 Chemotherapy Regimens 17

2.10 GlobalData Pipeline Report Guidance 20

3 Testicular Cancer Therapeutics: Market Characterization 21

3.1 Testicular Cancer Therapeutics Market Size (2005-2010) – Global 21

3.2 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Global 22

3.3 Testicular Cancer Therapeutics Market Size (2005-2010) – The US 23

3.4 Testicular Cancer Therapeutics Market Forecast (2010-2017) – The US 24

3.5 Testicular Cancer Therapeutics Market Size (2005-2010) – France 25

3.6 Testicular Cancer Therapeutics Market Forecast (2010-2017) – France 26

3.7 Testicular Cancer Therapeutics Market Size (2005-2010) – Germany 27

3.8 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Germany 28

3.9 Testicular Cancer Therapeutics Market Size (2005-2010) – Italy 29

3.10 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Italy 30

3.11 Testicular Cancer Therapeutics Market Size (2005-2010) – Spain 31

3.12 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Spain 32

3.13 Testicular Cancer Therapeutics Market Size (2005-2010) – The UK 33

3.14 Testicular Cancer Therapeutics Market Forecast (2010-2017) – The UK 34

3.15 Testicular Cancer Therapeutics Market Size (2005-2010) – Japan 35

3.16 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Japan 36

3.17 Drivers and Restraints for the Testicular Cancer Market 37

3.17.1 Drivers of the Testicular Cancer Therapeutics Market 37

3.17.2 Barriers for the Testicular Cancer Market 37

3.18 Opportunity and Unmet Need Analysis 38

3.19 Key Takeaway 38

4 Testicular Cancer Therapeutics: Competitive Assessment 39

4.1 Overview 39

4.1.1 Strategic Competitor Assessment 40

4.2 Major Marketed Product Profiles in the Testicular Cancer Therapeutics Market 40

4.2.1 Drugs Acting by Influencing Structure and Function of Deoxyribo Nucleic Acid (DNA) 40

4.2.2 Drugs Acting by Interfering with Microtubule Assembly 42

4.2.3 Drugs Acting by Inhibiting Biosynthesis of Nucleic Acids 42

4.3 Key Takeaway 42

5 Testicular Cancer Therapeutics: Pipeline Assessment 43

5.1 Overview 43

5.2 Strategic Pipeline Assessment 43

5.2.1 Technology Trends Analytic Framework 43

5.3 Testicular Cancer Therapeutics Pipeline Analysis – Pipeline by Clinical Phases of Development 44

5.3.1 Testicular Cancer Therapeutics – Phase II Clinical Pipeline 44

5.3.2 Testicular Cancer Therapeutics – Phase I Clinical Pipeline 44

5.4 Testicular Cancer Therapeutics Pipeline by Mechanism of Action 45

5.5 Testicular Cancer Therapeutics Technology Trends Analytical Framework 46

5.6 Testicular Cancer Therapeutics Pipeline by Monotherapy and Combination Therapy 48

5.7 Testicular Cancer Therapeutics – Promising Drugs under Clinical Development 48

5.8 Key Takeaway 48

6 Testicular Cancer Therapeutics: Clinical Trials Mapping 49

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 49

6.2 Clinical Trials by Phase 50

6.3 Clinical Trials by Trial Status 51

6.4 Prominent Sponsors 53

6.5 Top Companies Participating in Therapeutics Clinical Trials 54

7 Testicular Cancer Therapeutics: Strategic Assessment 55

7.1 Key Events Impacting the Future Market 55

7.2 Future Market Competition Scenario 56

8 Global Testicular Cancer Therapeutics Market: Future Players 57

8.1 Introduction 57

8.2 ZIOPHARM Oncology, Inc 58

8.2.1 Company Overview 58

8.2.2 Financial Overview 58

8.2.3 Business Overview 58

8.2.4 Oncology Pipeline 59

8.2.5 Testicular Cancer Therapeutics Pipeline 59

8.2.6 Deals, Alliance and Partnerships 59

9 Global Testicular Cancer Therapeutics Market: Appendix 60

9.1 Definitions 60

9.2 Acronyms 60

9.3 Methodology 61

9.3.1 Coverage 61

9.3.2 Secondary Research 62

9.3.3 Forecasting 62

9.3.4 Primary Research 65

9.3.5 Expert Panel Validation 65

9.4 Contact Us 65

9.5 Disclaimer 65

9.6 Bibliography 66

1.1 List of Tables

Table 1: Classification of Tumours Based on How Well the Tumours are Expected to Respond to Treatment 14

Table 2: Testicular Cancer Chemotherapy Regimens 19

Table 3: Testicular Cancer Therapeutics, Major Market, Global, Revenue ($m), 2005–2010 21

Table 4: Testicular Cancer Therapeutics, Major Market, Global, Forecast ($m), 2010–2017 22

Table 5: Testicular Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010 23

Table 6: Testicular Cancer Therapeutics Market, the US, Forecasts ($m), 2010–2017 24

Table 7: Testicular Cancer Therapeutics, France, Revenue ($m), 2005–2010 25

Table 8: Testicular Cancer Therapeutics Market, France, Forecasts ($m), 2010–2017 26

Table 9: Testicular Cancer Therapeutics, Germany, Revenue ($m), 2005–2010 27

Table 10: Testicular Cancer Therapeutics Market, Germany, Forecasts ($m), 2010–2017 28

Table 11: Testicular Cancer Therapeutics, Italy, Revenue ($m), 2005–2010 29

Table 12: Testicular Cancer Therapeutics Market, Italy, Forecasts ($m), 2010–2017 30

Table 13: Testicular Cancer Therapeutics, Spain, Revenue ($m), 2005–2010 31

Table 14: Testicular Cancer Therapeutics Market, Spain, Forecasts ($m), 2010–2017 32

Table 15: Testicular Cancer Therapeutics, the UK, Revenue ($m), 2005–2010 33

Table 16: Testicular Cancer Therapeutics Market, the UK, Forecasts ($m), 2010–2017 34

Table 17: Testicular Cancer Therapeutics, Japan, Revenue ($m), 2005–2010 35

Table 18: Testicular Cancer Therapeutics Market, Japan, Forecasts ($m), 2010–2017 36

Table 19: Testicular Cancer Chemotherapy Regimens 41

Table 20: Testicular Cancer Therapeutics – Phase II Clinical Pipeline, 2011 44

Table 21: Testicular Cancer Therapeutics – Phase I Clinical Pipeline, 2011 44

Table 22: Testicular Cancer Therapeutics, Global, Clinical Trials by Country, 2011 49

Table 23: Testicular Cancer Therapeutics, Global, Clinical Trials by Phase, 2011 50

Table 24: Testicular Cancer Therapeutics, Global, Clinical Trials by Status of Development, 2011 51

Table 25: Testicular Cancer Therapeutics, Prominent Sponsors, 2011 53

Table 26: Testicular Cancer Therapeutics, Clinical Trials of Companies by Phase, 2011 54

Table 27: ZIOPHARM Oncology Inc – Oncology Pipeline, 2011 59

Table 28: ZIOPHARM Oncology Inc – Molecules in Pipeline for Testicular Cancer, 2011 59

Table 29: ZIOPHARM Oncology Inc., Deals 59

1.2 List of Figures

Figure 1: Treatment of Testicular Cancer by Stage 10

Figure 2: Treatment of Testicular Cancer by Stage 11

Figure 3: Treatment of Testicular Cancer by Stage 12

Figure 4: Stages of Testicular Cancer 14

Figure 5: Testicular Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010 21

Figure 6: Testicular Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017 22

Figure 7: Testicular Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010 23

Figure 8: Testicular Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017 24

Figure 9: Testicular Cancer Therapeutics Market, France, Revenue ($m), 2005–2010 25

Figure 10: Testicular Cancer Therapeutics Market, France, Forecast ($m), 2010–2017 26

Figure 11: Testicular Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010 27

Figure 12: Testicular Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017 28

Figure 13: Testicular Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010 29

Figure 14: Testicular Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017 30

Figure 15: Testicular Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010 31

Figure 16: Testicular Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017 32

Figure 17: Testicular Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010 33

Figure 18: Testicular Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017 34

Figure 19: Testicular Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010 35

Figure 20: Testicular Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017 36

Figure 21: Opportunity and Unmet Need in the Testicular Cancer Therapeutics Market, 2011 38

Figure 22: Strategic Competitor Assessment of the Major Marketed Products in Testicular Cancer, 2011 39

Figure 23: Testicular Cancer Pipeline Products by Phase of Clinical Development, 2011 43

Figure 24: Testicular Cancer Pipeline by Clinical Phases of Development 44

Figure 25: Testicular Cancer Therapeutics – Pipeline by Mechanism of Action (%), 2011 45

Figure 26: Technology Trends Analytical Framework for the Testicular Cancer Therapeutics Pipeline, 2011 46

Figure 27: Technology Trends Analytical Framework for the Testicular Cancer Therapeutics Pipeline, 2011 47

Figure 28: Testicular Cancer Pipeline Products by Monotherapy and Combination Therapy, 2011 48

Figure 29: Testicular Cancer Therapeutics – Clinical Trials by Country, 2011 49

Figure 30: Testicular Cancer Therapeutics, Major Markets – Clinical Trials by Phase, 2011 50

Figure 31: Testicular Cancer Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 51

Figure 32: Testicular Cancer Therapeutics, Major Markets, Prominent Sponsors, 2011 52

Figure 33: Testicular Cancer Therapeutics, Prominent Sponsors, 2011 53

Figure 34: Testicular Cancer Therapeutics, Major Markets, Clinical Trials of Companies by Phase, 2011 54

Figure 35: Testicular Cancer Therapeutics Market, Drivers and Restraints, 2011 55

Figure 36: Implications for Future Market Competition in the Testicular Cancer Therapeutics Market, 2011 56

Figure 37: Testicular Cancer Therapeutics, Clinical Pipeline by Company, 2011 57

Figure 38: GlobalData Market Forecasting Model 64

Companies Mentioned

ZIOPHARM Oncology, Inc

To order this report:

Pathology Industry: Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker